Teva has entered into a new joint venture with pharma partners for novel therapeutic approaches in neurodegenerative diseases.
Teva Pharmaceutical, a big pharma company, announced that a new and unique neuroscience research collaboration has been established with their pharma partners to focus on novel therapeutic approaches to managing some of the most challenging diseases that society faces today.
This initiative, the National Network of Excellence in Neuroscience, seeks to harness that expertise in a community drawn from 10 of the leading universities and teaching hospitals in Israel.
Working as an open-network, the NNE is directed towards the discovery and development of new treatments and approaches to counter the devastating effects of neurological, neurodegenerative and psychiatric illness.
It brings the pharma partners together and provides a working interface with industry, where experts in drug development from Teva will interact with academic researchers in order to increase the potential to translate basic science into therapeutic options.
The National Network of Excellence in Neuroscience pharma partners include The Hebrew University, The Weizmann Institute, The Technion, Ben Gurion university, Tel Aviv University, Sourasky Medical Center, Sheba Medical Center, Rabin Medical Center, Bar Ilan University and the University of Haifa.
Report: Partnering Deals and Alliances with Teva
Report: Alzheimer’s Disease Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity